Quantitative Risk for Single-Positive Lupus Anticoagulant Results With Different Anticoagulants.
Where this comes from
- Record sourced from PubMed, PMID 36940149.
- Also identified by DOI 10.1093/ajcp/aqac183.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical experts recommend against testing for lupus anticoagulant (LAC) during anticoagulation. We quantitated the risk of a single-positive dilute Russell viper venom time (dRVVT) result or partial thromboplastin time-based phospholipid neutralization (PN) result on anticoagulation. Any anticoagulation led to a fourfold greater likelihood of single-positive results, primarily by rivaroxaban (odds ratio [OR] = 8.6) and warfarin (OR = 6.6), resulting in a positive dRVVT test with a normal PN test. Heparin and apixaban were twofold more likely to show single-positive results, but enoxaparin did not show significant single positivity. Our results quantitatively support experts' avoidance of LAC testing during anticoagulation.
Medical subject headings
- Anticoagulants
- Antiphospholipid Syndrome